PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness
Abstract Programmed death ligand-1 (PD-L1), a promising antitumor target, has proven clinical value against many malignancies. However, the PD-L1 content of Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and its correlation with clinical outcomes remain unclear. This study aimed to investiga...
Guardado en:
Autores principales: | Kun Chang, Yuanyuan Qu, Bo Dai, Jian-Yuan Zhao, Hualei Gan, Guohai Shi, Yiping Zhu, Yijun Shen, Yao Zhu, Hailiang Zhang, Dingwei Ye |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1bdfc57c88ee4522a2dca323ac365b0a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma
por: Jun Cheng, et al.
Publicado: (2020) -
Estradiol increases risk of topoisomerase IIβ-mediated DNA strand breaks to initiate Xp11.2 translocation renal cell carcinoma
por: Qiancheng Shi, et al.
Publicado: (2021) -
Xp11.2 Translocation Renal Cell Carcinoma With TFE3 Rearrangement: Distinct Morphological Features and Prognosis With Different Fusion Partners
por: Yan Ge, et al.
Publicado: (2021) -
Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status
por: Junlong Wu, et al.
Publicado: (2017) -
Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
por: Weijie Gu, et al.
Publicado: (2017)